Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Official title: A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Status: Closed to new participants
Description:
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Who can take part: 15000 participants planned.
Enrollment status: Closed to enrollment. The study started 21 December 2018 and is expected to finish 01 December 2050.
Source: ClinicalTrials.gov, NCT03661866 (https://clinicaltrials.gov/study/NCT03661866).
Start date: December 21, 2018
Completion date: December 01, 2050
Organizer: Target PharmaSolutions, Inc.
Link: https://clinicaltrials.gov/study/NCT03661866
The registry does not list a contact for this study. Use the link above to reach the study record on ClinicalTrials.gov.
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- PTSD in Vitiligo?
Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...
- Which therapy has minimal side-effects?
Dead Sea climatotherapy is a unique and highly effective treatment option for vitiligo, offering a top-tier safety profile and natural therapeutic benefits. Its combination of p...
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.